Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

Core Viewpoint - Ipsen has received a positive opinion from the CHMP of the EMA for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic neuroendocrine tumors, based on the CABINET Phase III trial results, with a final decision expected soon [1][6]. Company Summary - Ipsen is a global biopharmaceutical company focused on oncology, rare diseases, and neuroscience, with nearly 100 years of development experience [11]. - The company has exclusive rights for the commercialization and clinical development of Cabometyx outside the U.S. and Japan, while Exelixis retains rights in the U.S. [8]. Industry Summary - The incidence of neuroendocrine tumors (NETs) is increasing, with a higher prevalence than pancreatic or bladder cancer, and treatment options are often limited upon disease progression [2]. - The CABINET Phase III trial demonstrated significant efficacy for Cabometyx, showing median progression-free survival (PFS) of 13.8 months for pNET patients compared to 4.4 months for placebo [7]. - For advanced gastrointestinal and lung NETs, the five-year survival rates are 68% and 55%, respectively, while advanced pNET has a poor prognosis with a five-year survival rate of only 23% [3].